Form 4: Celldex Therapeutics Director, Karen L. Shoos, Acquires 16,500 Stock Options

Karen L. Shoos, a director of Celldex Therapeutics, acquired 16,500 non-qualified stock options on June 13, 2024, according to a recent SEC filing.

Summary

• On June 13, 2024, Karen L. Shoos, a director of Celldex Therapeutics, Inc., acquired 16,500 non-qualified stock options.
• The options were granted pursuant to the company's 2021 Omnibus Equity Incentive Plan.
• The exercise price of the options is $36.43.
• The options become exercisable on June 13, 2025, and expire on June 13, 2034.
• Following the transaction, Ms. Shoos directly owns 16,500 derivative securities.

Sentiment

Score: 6

Explanation: The document is a routine SEC filing related to stock option grants, which is generally neutral. It reflects standard compensation practices.

Positives

• The grant of stock options aligns the director's interests with those of the shareholders.
• The 2021 Omnibus Equity Incentive Plan is designed to attract and retain key personnel.

Industry Context

Stock option grants are a common practice in the biotechnology industry to incentivize and retain directors and key employees.

Comparison to Industry Standards

• Stock option grants are a typical component of executive compensation packages in the biotech industry, similar to companies like Amgen, Regeneron, and Gilead Sciences.
• The size of the grant is likely determined by factors such as the director's role, company performance, and industry benchmarks for executive compensation.

Stakeholder Impact

• The stock option grant could potentially increase shareholder value if the director's performance leads to company growth.
• The grant incentivizes the director to act in the best interests of the company and its shareholders.

Key Dates